Compare Visa Inc (V) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Visa Inc vs Zoetis Inc — how do they compare? Visa Inc trades at $358.67 (market cap $671.74B), while Zoetis Inc trades at $72.35 (market cap $31.14B). The key difference: Visa Inc is far larger — about 21.6× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| V | ZTS | |
|---|---|---|
Market Cap | $671.74B | $31.14B |
Volume | 10,431,336 | — |
Sector | Financials | Health |
52-Week High | $370.47 | $156.76 |
52-Week Low | $295.52 | $71.91 |
Enterprise Value | $682.32B | $38.70B |
Dividend Yield | 0.74% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Visa (V) trades at $358.92, down 0.66% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 and Q2 2026 earnings beats, with revenue growth from $40B in 2025 to a projected $44.5B in 2026. Analyst consensus is overwhelmingly bullish, with an 85.48% buy rating and a $426.31 price target, suggesting 19% upside. Recent news highlights Visa's AI initiatives, such as Intelligent Commerce Connect, to enhance payment efficiency.
Visa's outlook remains positive due to consistent earnings outperformance, high profit margins, and strategic AI adoption. Risks include rising fintech competition and regulatory pressures. The stock presents a long-term growth opportunity, supported by solid fundamentals and institutional confidence, though investors should monitor competitive and macroeconomic headwinds.
Zoetis (ZTS) trades at $74.86, up 3.03% today but facing bearish technical signals with 16 sell indicators. The company reported mixed Q2 2026 results, beating EPS estimates but missing revenue expectations, while cutting full-year guidance due to softer pet healthcare demand. Strong fundamentals include a 27.69% net margin and 64.91% ROE, though valuation metrics show a P/E of 12.29 and P/S of 3.41.
The stock presents a value opportunity with analyst consensus target of $94.90 (27% upside), but faces near-term headwinds from competitive pressures and class action lawsuits. Investors should weigh strong profitability against slowing growth in companion animal segments and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
